HBI Deals+Insights / News
UCB, a Belgian biopharma company, plans to divest its business in China, to CBC Group, a Singapore-based investment firm, and Mubadala, a global investment company from Abu Dhabi, for $680 million.
The deal, pending regulatory approval, is expected to close in Q4 2024 and includes UCB’s neurology and allergy portfolios, as well as its manufacturing site in Zhuhai, China.